The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 2 July 2014 Sopharma AD submitted for approval the signed merger agreement between Bulgarian Rose – Sevtopolis AD and Sopharma AD and all accompanying documents to the Financial Supervision Commission.

SOPHARMA AD (the “Company”) hereby informs that from 26 June 2014 up to and including 2 July 2014 the Company bought 27 776 own shares representing 0.021% of the share capital of the Company, to the total value of 115 083.07 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 4 999 048, representing 3.79% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that for June 2014 the Company recorded a decrease of sales revenues of 8% compared to the same period of 2013, including 7% decrease of domestic sales and 9% decrease of export sales, mainly due to the situation in eastern Ukraine.

During the past six months Sopharma AD recorded a decrease of sales revenues of 6%, including 2% increase of domestic sales and 8% decrease of export sales compared to 2013.

SOPHARMA AD (the “Company”) hereby informs that from 26 September 2013 up to and including 2 October 2013 the Company bought 13 735 own shares representing 0.01 % of the share capital of the Company, to the total value of 45 237.71  BGN on the Bulgarian Stock Exchange. The average price per share was 3.29 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 247 981, representing 3.98% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 3 July 2014 up to and including 9 July 2014 the Company bought 1 277 own shares representing 0.001% of the share capital of the Company, to the total value of 5 512.97 BGN on the Bulgarian Stock Exchange, the average price per share was 4.32 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 4 999 925, representing 3.79% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that for September 2013 the Company realized an increase of sales revenues of 12% compared to the same period of 2012, including 17% increase of domestic sales and 10% increase of export sales.

During the past nine months Sopharma AD recorded a decrease of sales revenues of 1%, including 6% increase of domestic sales and 3% decrease of export sales compared to the same period of 2012.

SOPHARMA AD (the “Company”) hereby informs that from 10 July 2014 up to and including 16 July 2014 the Company bought 24 177 own shares representing 0.018% of the share capital of the Company, to the total value of 99 990.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 024 102, representing 3.81% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 3 October 2013 up to and including 9 October 2013 the Company bought 42 014 own shares representing 0.032% of the share capital of the Company, to the total value of 136 725.01  BGN on the Bulgarian Stock Exchange. The average price per share was 3.254 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 289 995, representing 4.01% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 17 July 2014 up to and including 23 July 2014 the Company bought 6 476 own shares representing 0.005% of the share capital of the Company, to the total value of 26 747.69 BGN on the Bulgarian Stock Exchange, the average price per share was 4.13 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 030 578, representing 3.81% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 10 October 2013 up to and including 16 October 2013 the Company bought 7 650 own shares representing 0.0058% of the share capital of the Company, to the total value of 24 998.10  BGN on the Bulgarian Stock Exchange. The average price per share was 3.27 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 297 645, representing 4.01% of the share capital of the Company.